COST OF CARE COMPARISON OF ELRANATAMAB-BCMM AND TECLISTAMAB-CQYV IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)

被引：0
|
作者：
Shah, B. [1 ]
Sandin, R. [2 ]
Liu, Y. [3 ]
Hu, Y. [4 ]
Schepart, A. [5 ]
Hughes, D. [6 ]
Hart, J. [7 ]
Hlavacek, P. [7 ]
机构：
[1] Boston Med Ctr, Boston, MA USA
[2] Pfizer AB, Stockholm, Sweden
[3] Cytel, Rotterdam, Netherlands
[4] Ingress Hlth Cytel Co, Riverside, CA USA
[5] Pfizer Inc, New York, NY USA
[6] Pfizer Inc, Dorchester, MA USA
[7] Pfizer Inc, Boston, MA USA
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE14
引用
收藏
页码：S59 / S59
页数：1
相关论文
共 50 条
  • [31] Higher Teclistamab Step-up Dosing in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Results from the Majestec-1 Trial
    Matous, Jeffrey, V
    van de Donk, Niels W. C. J.
    Oriol, Albert
    Garfall, Alfred L.
    Rodriguez-Otero, Paula
    Chalopin, Thomas
    Dachs, Laura Rosinol
    Uttervall, Katarina
    Mateos, Maria- Victoria
    Trancucci, Danielle
    Carde, Natalia Quijano
    Hodin, Caroline
    Stephenson, Tara
    Zuppa, Athena
    Chastain, Katherine
    Karlin, Lionel
    BLOOD, 2024, 144 : 4749 - 4750
  • [32] Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma
    Girgis, Suzette
    Lin, Shun Xin Wang
    Pillarisetti, Kodandaram
    Verona, Raluca
    Vieyra, Diego
    Casneuf, Tineke
    Fink, Damien
    Miao, Xin
    Chen, Yang
    Stephenson, Tara
    Banerjee, Arnob
    Hilder, Brandi W.
    Russell, Jeffery
    Infante, Jeffrey
    Elsayed, Yusri
    Smit, Jennifer
    Goldberg, Jenna D.
    BLOOD ADVANCES, 2023, 7 (04) : 644 - 648
  • [33] Efficacy of teclistamab against the current standard of care in patients with triple-exposed relapsed/refractory multiple myeloma (RRMM) in=3 lines of therapy: Comparison with clinical practice data in the LocoMMotion study
    Weisel, K.
    van de Donk, Wcj N.
    Moreau, P.
    Delforge, M.
    Einsele, H.
    Ghilotti, F.
    Diels, J.
    Elsada, A.
    Strulev, V
    Pei, L.
    Kobos, R.
    Smit, J.
    Slavcev, M.
    Mateos, M. -, V
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 304 - 304
  • [34] Efficacy of teclistamab in patients (pts) with heavily pretreated, relapsed/refractory multiple myeloma (RRMM), including those refractory to penta RRMM and BCMA (B-cell maturation antigen) directed therapy (BDT)
    Venkatesh, Priyanka
    Atrash, Shebli
    Paul, Barry
    Alkharabsheh, Omar
    Afrough, Aimaz
    Mahmoudjafari, Zahra
    Mushtaq, Muhammad Umair
    Hashmi, Hamza
    Davis, James A.
    Abdallah, Al-Ola A.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [35] Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma: Cohort a of MagnetisMM-3
    Shay, Gemma
    Bahlis, Nizar
    Tomasson, Michael H.
    Mohty, Mohamad
    Niesvizky, Ruben
    Nooka, Ajay
    Manier, Salomon
    Maisel, Christopher
    Jethava, Yogesh
    Martinez-Lopez, Joaquin
    Prince, H. Miles
    Arnulf, Bertrand
    Rodriguez-Otero, Paula
    Koehne, Guenther
    Touzeau, Cyrille
    Raje, Noopur
    Iida, Shinsuke
    Raab, Marc-Steffen
    Leip, Eric
    Sullivan, Sharon
    Conte, Umberto
    Viqueira, Andrea
    Lesokhin, Alexander
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 16 - 17
  • [36] Daratumumab with Pomalidomide and Dexamethasone at First Relapse in Relapsed and/or Refractory Multiple Myeloma ( RRMM) Patients
    不详
    BLOOD, 2021, 138
  • [37] Efficacy and Safety of Ruxolitinib and Steroids for Treating Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
    Berenson, James R.
    Silagan, Noemi
    To, Jennifer
    Spektor, Tanya M.
    Martinez, Daisy
    Sanchez, Armando J.
    Forouzan, Eli
    Swift, Regina
    Eades, Benjamin
    Schwartz, Gary
    Eshaghian, Shahrooz
    Boccia, Ralph V.
    Yang, Honghao Hank
    Lim, Stephen
    Vescio, Robert
    BLOOD, 2020, 136
  • [38] PRACTICE PATTERNS AND OUTCOMES IN ELDERLY US PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
    Romanus, D.
    Raju, A.
    Yong, C.
    Seal, B.
    Farrelly, E.
    Labotka, R.
    Jhaveri, M.
    Noga, S.
    Blazer, M.
    Parameswaran, H.
    HAEMATOLOGICA, 2016, 101 : 532 - 533
  • [39] Comparative effectiveness of teclistamab versus real-world treatments for patients with triple-class exposed (TCE), relapsed/refractory multiple myeloma (RRMM).
    Krishnan, Amrita Y.
    Nooka, Ajay K.
    Chari, Ajai
    Garfall, Alfred L.
    Martin, Thomas G.
    Nair, Sandhya
    Lin, Xiwu
    Qi, Keqin
    Londhe, Anil
    Pei, Lixia
    Eric, Ammann
    Kobos, Rachel
    Smit, Jennifer
    Parekh, Trilok V.
    Slavcev, Mary
    Usmani, Saad Zafar
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [40] Optec: A Phase 2 Study to Evaluate Outpatient Step-up Administration of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results
    Rifkin, Robert
    Schade, Henning
    Simmons, Gary
    Yasenchak, Christopher
    Fowler, Jessica
    Lin, Thomas S.
    Kang, Lijuan
    Xu, Weiming
    BLOOD, 2024, 144 : 4753 - 4754
12345